Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.19 USD
Change Today -0.0056 / -2.85%
Volume 233.7K
LPTN On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (LPTN) Key Developments

Lpath Appoints Gary Atkinson Interim Chief Executive Officer

Lpath Inc. announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpath's chief financial officer. Mr. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer. He also previously served as vice president of finance at Isis Pharmaceuticals, and as a financial consultant to Ichor Medical Systems. Earlier in his career, Mr. Atkinson served as the corporate controller at Loral Aerospace Corporation and as the director of financial planning at Cubic Corporation. Mr. Atkinson began his career at Ernst and Young. He is a graduate of Brigham Young University.

Lpath Inc. Initiates First-In-Human Dosing in Phase 1 Clinical Trial of Lpathomab

Lpath Inc. announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses. Lpathomab is an antibody targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral adiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury.

Lpath Inc. Announces Plan to Begin Lpathomab Clinical Trial

Lpath Inc. announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.

Lpath, Inc. Receives Non-Compliance Notice From NASDAQ

On July 9, 2015, Lpath, Inc. received a notice letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC indicating that, based upon the closing bid price of the company’s common stock for the last 30 consecutive business days, the company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq will provide the company with a period of 180 calendar days, or until January 5, 2016, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the company’s common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event that the company does not regain compliance within this 180-day period, the company may be eligible to seek an additional compliance period of 180 calendar days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq Staff that the company will not be able to cure the deficiency, or if the company is otherwise not eligible, Nasdaq will provide notice to the company that its common stock will be subject to delisting. The Notice does not result in the immediate delisting of the company’s common stock from the Nasdaq Capital Market. The company will continue to monitor the closing bid price of its common stock over the 180-day period to see if its closing bid price may increase based on its future filings with the Securities and Exchange Commission or any future announcements the company may be able to issue regarding its drug development programs and plans. The company will also consider its available options to regain compliance, including effecting a reverse stock split, which would be subject to the prior approval of the company’s stockholders. There can be no assurance that the company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements necessary for company to maintain the listing of its common stock on the Nasdaq Capital Market.

Lpath Reports Results for iSONEP™ in Patients with Wet Age-related Macular Degeneration

Lpath Inc. announced that its multicenter, Phase 2 "Nexus" clinical trial evaluating iSONEP™ in patients with wet age-related macular degeneration (wet AMD) did not meet its primary or key secondary endpoints. Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis®, Avastin® and Eylea® did not show any statistically significant improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy. Nexus is a prospective, randomized, double-masked, positive control, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet AMD. All enrolled patients had been subresponsive to treatment with anti-VEGF drugs, and had received at least three previous injections of an anti-VEGF drug. Nexus study patients each received four intravitreal injections over the 90 day dosing period. There were approximately 39 patients in each of the four treatment arms. The pre-specified primary endpoint of the study was mean change in best corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) from Day 0 to Day 120. At day 120, patients who received intravitreal injections of (i) 4.0 mg iSONEP alone lost a mean of 3.17 letters on the ETDRS, (ii) a combination of 0.5 mg iSONEP and anti-VEGF therapy gained a mean of 4.22 letters, (iii) a combination of 4.0 mg iSONEP and anti-VEGF therapy gained a mean of 3.63 letters, and (iv) an anti-VEGF therapy alone gained a mean of 4.34 letters. Full study results will be presented during the Retina Subspecialty Days in conjunction with the American Academy of Ophthalmology in Las Vegas, Nevada in November 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPTN:US $0.19 USD -0.0056

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at